MedTrace Logo

Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block

NCT03117140 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2018-07-03

Study results available
· View outcomes & findings →

Summary

This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain ropivacaine alone.

Conditions

  • Anesthesia, Local

Interventions

DRUG

Ropivacaine 0.75%

Only ropivacaine 0.75% is administered for this arm of the interscalene block

DRUG

Ropivacaine 0.75% + 300 mcg Buprenorphine

Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block

DRUG

Ropivacaine 0.75% + 75 mcg clonidine

Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block

DRUG

Ropivacaine 0.75% + 8 mg dexamethasone

Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block

Sponsors & Collaborators

  • Melinda Seering

    lead OTHER

Principal Investigators

  • Melinda Seering, M.D. · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03117140 on ClinicalTrials.gov